Download PDF
Fortschr Neurol Psychiatr 2002; 70(5): 234-242
DOI: 10.1055/s-2002-28431
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Atypische Antipsychotika in der Therapie der bipolaren affektiven Störung

Atypical Antipsychotics in the Treatment of Bipolar Affective DisordersE.  Hilger1 , C.  Barnas1
  • 1Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Wien
Further Information

Publication History

Publication Date:
08 May 2002 (online)

    Permissions and Reprints

Zusammenfassung

Antipsychotischen Substanzen kommt in der Behandlung bipolarer affektiver Störungen ein bedeutender klinischer Stellenwert zu. Trotz des gut dokumentierten antimanischen Effektes klassischer Antipsychotika ist der Einsatz dieser Substanzen, nicht zuletzt wegen des weitgehenden Fehlens stimmungsstabilisierender Eigenschaften und des erhöhten Risikos für Spätdyskinesien bei affektiven Patienten, mit einer Reihe von Nachteilen verbunden. Mit Entwicklung der neuen, sog. atypischen Antipsychotika ist die Pharmakotherapie der bipolaren Störung um vielversprechende Dimensionen erweitert worden. Gut untersucht wurden die thymoleptischen Eigenschaften von Clozapin, Risperidon und Olanzapin. Für Clozapin und Olanzapin werden ausgeprägtere antimanische als antidepressive Eigenschaften vermutet, Risperidon hingegen dürfte eine stärkere antidepressive als antimanische Wirkkomponente aufweisen. Dieser Artikel bietet einen Überblick über die vorliegenden Studien zur Wirksamkeit atypischer Antipsychotika in der Indikation der bipolaren Störung, darüber hinaus werden mögliche Arzneimittelinteraktionen zwischen Antipsychotika und anderen stimmungsstabilisierenden Pharmaka auf Basis des Cytochrom-P450-Systems diskutiert. Zusammenfassend ist anzunehmen, dass atypische Antipsychotika wertvolle Optionen in der Pharmakotherapie der bipolaren Störung darstellen. Zur Evaluierung des Stellenwertes einzelner Substanzen in dieser Indikation bedarf es jedoch weiterer kontrollierter Untersuchungen.

Abstract

Antipsychotics are commonly used in the treatment of bipolar affective disorder. The use of conventional antipsychotic agents, though effective as antimanic agents, is associated with a number of limitations such as their acute side effect profile and their unsufficient mood stabilizing activity. In addition, exposure to conventional neuroleptics poses a risk for the development of tardive dyskinesia, especially in mood disorder patients. Growing evidence suggests that the novel, so-called atypical neuroleptics may offer a number of advantages in the treatment of bipolar disorder, including their thymoleptic activity and minimal risk for acute and long-term extraypyramidal symptoms. Clinical experience with clozapine and olanzapine as mood stabilizers suggests greater antimanic than antidepressant properties, while risperidone may have greater antidepressant properties with some liability for triggering or exacerbating mania. The mood stabilizing properties of further atypical drugs are currently under investigation. This review focuses on the use of atypical antipsychotics in the treatment of bipolar disorder. We also present an overview concerning potential pharmakokinetic interactions based on the cytochrome P450 enzyme system when antipsychotics are combined with other mood stabilizing compounds. In conclusion, atypical antipsychotics should come to play an increasingly important role in the acute and long-term management of bipolar disorder, but there is a clear need for further controlled trials in this indication.

Literatur

  • 1 Goodwin F K, Jamison K R. Manic-Depressive Illness. New York: Oxford University Press 1990
    Google Scholar
  • 2 Prien R F, Gelenberg A J. Alternatives to lithium for preventive treatment of bipolar disorder.  Am J Psychiatry. 1989;  46(7) 840-848
    PubMedGoogle Scholar
  • 3 Post R M, Ketter T A, Denicoff K, Pazzaglia P J, Leverich G S, Marangell L B, Callahan A M, George M S, Frye M A. The place of anticonvulsant therapy in bipolar illness.  Psychopharmacology. 1996;  128(2) 115-129
    CrossrefPubMedGoogle Scholar
  • 4 Himmelhoch J M, Garfinkel M E. Sources of lithium resistance in mixed mania.  Psychopharmacol Bull. 1986;  22(3) 613-620
    PubMedGoogle Scholar
  • 5 Dunner D L, Fieve R R. Clinical factors in lithium carbonate prophylaxis failure.  Arch Gen Psychiatry. 1974;  30(2) 229-233
    CrossrefPubMedGoogle Scholar
  • 6 Gitlin M J, Swendsen J, Heller T L, Hammen C. Relapse and impairment in bipolar disorder.  Am J Psychiatry. 1995;  152(11) 1635-1640
    PubMedGoogle Scholar
  • 7 Denicoff K D, Smith-Jackson E E, Disney E R, Ali S O, Leverich G S, Post R M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.  J Clin Psychiatry. 1997;  58(11) 470-478
    PubMedGoogle Scholar
  • 8 Sernyak M J, Godleski L S, Griffin R A, Mazure C M, Woods S W. Chronic neuroleptic exposure in bipolar outpatients.  J Clin Psychiatry. 1997;  58(5) 193-195
    PubMedGoogle Scholar
  • 9 Sernyak M J, Woods S W. Chronic neuroleptic use in manic-depressive illness.  Psychopharmacol Bull. 1993;  29(3) 375-381
    PubMedGoogle Scholar
  • 10 Verdoux H, Gonzales B, Takei N, Bourgeois M. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients.  J Affect Disord. 1996;  38(2 - 3) 81-87
    CrossrefPubMedGoogle Scholar
  • 11 Johnson G, Gershon S, Burdock E I, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states.  Br J Psychiatry. 1971;  119(550) 267-276
    PubMedGoogle Scholar
  • 12 Spring G, Schweid D, Gray C, Steinberg J, Horwitz M. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states.  Am J Psychiatry. 1970;  126(9) 1306-1310
    PubMedGoogle Scholar
  • 13 Platman S R. A comparison of lithium carbonate and chlorpromazine in mania.  Am J Psychiatry. 1970;  127(3) 351-353
    PubMedGoogle Scholar
  • 14 Prien R F, Caffey Jr E M, Klett C J. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Report of the Veterans Administration and National Institute of Mental Health collaborative study group.  Arch Gen Psychiatry. 1972;  27(2) 182-189
    PubMedGoogle Scholar
  • 15 Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol.  Arch Gen Psychiatry. 1975;  32(1) 34-42
    PubMedGoogle Scholar
  • 16 McElroy S L, Keck P E, Stanton S P, Tugrul K C, Bennett J A, Strakowski S M. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.  J Clin Psychiatry. 1996;  57(4) 142-146
    PubMedGoogle Scholar
  • 17 Grossi E, Saccetti E, Vita A. Carbamazepine vs. chlorpromazine in manics: a double blind trial. In: Emrich HM, Okuma T, Muller AA (Eds.) Anticonvulsants in affective disorders Amsterdam, The Netherlands: Excerpta Medica 1984: 177-187
    Google Scholar
  • 18 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study.  Psychopharmacology. 1979;  66(3) 211-217
    CrossrefPubMedGoogle Scholar
  • 19 Janicak P G, Bresnahan D B, Sharma R, Davis J M, Comaty J E, Malinick C. A comparison of thiothixene with chlorpromazine in the treatment of mania.  J Clin Psychopharmacol. 1988;  8(1) 33-37
    PubMedGoogle Scholar
  • 20 Tohen M, Zarate Jr C A. Antipsychotic agents and bipolar disorder.  J Clin Psychiatry. 1998;  59 Suppl 1 38-48
    PubMedGoogle Scholar
  • 21 Ahlfors U G, Baastrup P C, Dencker S J, Elgen K, Lingjaerde O, Pedersen V, Schou M, Aaskoven O. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium.  Acta Psychiatr Scand. 1981;  64(3) 226-237
    PubMedGoogle Scholar
  • 22 Peselow E D, Fieve R R, Difiglia C, Sanfilipo M P. Lithium prophylaxis of bipolar illness. The value of combination treatment.  Br J Psychiatry. 1994;  164(2) 208-214
    PubMedGoogle Scholar
  • 23 Cole J O, Gardos G, Boling L A, Marby D, Haskell D, Moore P. Early dyskinesia-vulnerability.  Psychopharmacology. 1992;  107(4) 503-510
    PubMedGoogle Scholar
  • 24 Gardos G, Teicher M H, Lipinski Jr J F, Matthews J D, Morrison L, Conley C, Cole J O. Quantitative assessment of psychomotor activity in patients with neuroleptic-induced akathisia.  Prog Neuropsychopharmacol Biol Psychiatry. 1992;  16(1) 27-37
    PubMedGoogle Scholar
  • 25 Davis K L, Berger P A, Hollister L E. Tardive dyskinesia and depressive illness.  Psychopharmacol Commun. 1976;  2(2) 125-130
    PubMedGoogle Scholar
  • 26 Rosenbaum A H, Niven R G, Hanson N P, Swanson D W. Tardive dyskinesia: relationship with a primary affective disorder.  Dis Nerv Syst. 1977;  38(6) 423-427
    PubMedGoogle Scholar
  • 27 Jeste D V, Wyatt R J. Understanding and treating tardive dyskinesia. New York: Guilford Press 1982
    Google Scholar
  • 28 Glenthoj B, Hemmingsen R, Allerup P, Bolwig T G. Intermittent versus continuous neuroleptic treatment in a rat model.  Eur J Pharmacol. 1990;  190(3) 275-286
    CrossrefPubMedGoogle Scholar
  • 29 Keck Jr P E, McElroy S L, Strakowski S M, Soutullo C A. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.  J Clin Psychiatry. 2000;  61 Suppl 4 33-8
    PubMedGoogle Scholar
  • 30 Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis.  Psychosomatics. 1984;  25(2) 135-138
    PubMedGoogle Scholar
  • 31 Yassa R, Ghadirian A M, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients.  J Clin Psychiatry. 1983;  44(11) 410-412
    PubMedGoogle Scholar
  • 32 Mukherjee S, Rosen A M, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients.  Arch Gen Psychiatry. 1986;  43(4) 342-346
    PubMedGoogle Scholar
  • 33 Lal K P, Saxena S, Mohan D. Tardive dystonia alternating with mania.  Biol Psychiatry. 1988;  23(3) 312-316
    CrossrefPubMedGoogle Scholar
  • 34 Sachdev P S. Depression-dependent exacerbation of tardive dyskinesia.  Br J Psychiatry. 1989;  155 253-255
    PubMedGoogle Scholar
  • 35 Wegner J T, Catalano F, Gibralter J, Kane J M. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology.  Arch Gen Psychiatry. 1985;  42(9) 860-865
    PubMedGoogle Scholar
  • 36 Wegner J T, Kane J M, Weinhold P, Woerner M, Kinon B, Lieberman J. Cognitive impairment in tardive dyskinesia.  Psychiatry Res. 1985;  16(4) 331-317
    CrossrefPubMedGoogle Scholar
  • 37 Hilger E, Kasper S. Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders.  Wien Klin Wochenschr. 2000;  112(24) 1031-1038
    PubMedGoogle Scholar
  • 38 Ghaemi S N. New treatments for bipolar disorder: the role of atypical neuroleptic agents.  J Clin Psychiatry. 2000;  61 Suppl 14 33-42
    PubMedGoogle Scholar
  • 39 Brown E S, Thomas N R, Carmody T, Mahadi S, Nejtek V A. Atypical antipsychotics in bipolar and schizoaffective disorders.  Pharmacopsychiatry. 2001;  34(2) 80-81
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Soares J C. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling.  Int Clin Psychopharmacol. 2000;  15(4) 183-196
    PubMedGoogle Scholar
  • 41 Keck Jr P E, McElroy S L, Strakowski S M. Anticonvulsants and antipsychotics in the treatment of bipolar disorder.  J Clin Psychiatry. 1998;  59 Suppl 6 74-81
    PubMedGoogle Scholar
  • 42 Gelenberg A J, Hopkins H S. Antipsychotics in bipolar disorder.  J Clin Psychiatry. 1996;  57 Suppl 9 49-52
    PubMedGoogle Scholar
  • 43 Tohen M, Jacobs T G, Feldman P D. Onset of action of antipsychotics in the treatment of mania.  Bipolar Disord. 2000;  2(2) 261-268
    CrossrefPubMedGoogle Scholar
  • 44 Zarate Jr C A, Tohen M, Baldessarini R J. Clozapine in severe mood disorders.  J Clin Psychiatry. 1995;  56(9) 411-417
    PubMedGoogle Scholar
  • 45 Frye M A, Ketter T A, Altshuler L L, Denicoff K, Dunn R T, Kimbrell T A, Cora-Locatelli G, Post R M. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics.  J Affect Disord. 1998;  48(2 - 3) 91-104
    CrossrefPubMedGoogle Scholar
  • 46 Battegay R, Cotar B, Fleischhauer J, Rauchfleisch U. Results and side effects of treatment with clozapine (leponex R).  Compr Psychiatry. 1977;  18(5) 423-428
    CrossrefPubMedGoogle Scholar
  • 47 Leppig M, Bosch B, Naber D, Hippius H. Clozapine in the treatment of 121 out-patients.  Psychopharmacology (Berl). 1989;  99 77-79
    CrossrefPubMedGoogle Scholar
  • 48 Naber D, Hippius H. The European experience with use of clozapine.  Hosp Community Psychiatry. 1990;  41(8) 886-890
    PubMedGoogle Scholar
  • 49 Ciapparelli A, Dell'Osso L, Pini S, Chiavacci M C, Fenzi M, Cassano G B. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study.  J Clin Psychiatry. 2000;  61(5) 329-334
    PubMedGoogle Scholar
  • 50 McElroy S L, Dessain E C, Pope Jr H G, Cole J O, Keck Jr P E, Frankenberg F R, Aizley H G, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.  J Clin Psychiatry. 1991;  52(10) 411-414
    PubMedGoogle Scholar
  • 51 Zarate Jr C A, Tohen M, Banov M D, Weiss M K, Cole J O. Is clozapine a mood stabilizer?.  J Clin Psychiatry. 1995;  56(3) 108-112
    PubMedGoogle Scholar
  • 52 Suppes T, Rush A J, Webb A, Carmody T, Kraemer H. A one year randomized trial of clozapine vs. usual care in bipolar I patients.  Biol Psychiatry. 1996;  39 531
    PubMedGoogle Scholar
  • 53 Calabrese J R, Meltzer H Y, Markovitz P J. Clozapine prophylaxis in rapid cycling bipolar disorder.  J Clin Psychopharmacol. 1991;  11(6) 396-397
    PubMedGoogle Scholar
  • 54 Green A I, Tohen M, Patel J K, Banov M, DuRand C, Berman I, Chang H, Zarate Jr C, Posener J, Lee H, Dawson R, Richards C, Cole J O, Schatzberg A F. Clozapine in the treatment of refractory psychotic mania.  Am J Psychiatry. 2000;  157(6) 982-998
    CrossrefPubMedGoogle Scholar
  • 55 Kimmel S E, Calabrese J R, Woyshville M J, Meltzer H Y. Clozapine in treatment-refractory mood disorders.  J Clin Psychiatry. 1994;  55 Suppl B 91-93
    PubMedGoogle Scholar
  • 56 Calabrese J R, Kimmel S E, Woyshville M J, Rapport D J, Faust C J, Thompson P A, Meltzer H Y. Clozapine for treatment-refractory mania.  Am J Psychiatry. 1996;  153(6) 759-764
    CrossrefPubMedGoogle Scholar
  • 57 Suppes T, McElroy S L, Gilbert J, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania.  Biol Psychiatry. 1992;  32(3) 270-280
    CrossrefPubMedGoogle Scholar
  • 58 Frye M A, Altshuler L L, Bitran J A. Clozapine in rapid cycling bipolar disorder.  J Clin Psychopharmacol. 1996;  16(1) 87-90
    CrossrefPubMedGoogle Scholar
  • 59 Suppes T, Phillips K A, Judd C R. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases.  Biol Psychiatry. 1994;  36(5) 338-340
    CrossrefPubMedGoogle Scholar
  • 60 Banov M D, Zarate Jr C A, Tohen M, Scialabba D, Wines Jr J D, Kolbrener M, Kim J W, Cole J O. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up.  J Clin Psychiatry. 1994;  55(7) 295-300
    PubMedGoogle Scholar
  • 61 Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.  N Engl J Med. 1993;  329(3) 162-167
    CrossrefPubMedGoogle Scholar
  • 62 Miller D D. Review and management of clozapine side effects.  J Clin Psychiatry. 2000;  61 Suppl 8 14-17
    PubMedGoogle Scholar
  • 63 Denney D, Stevens J R. Clozapine and seizures.  Biol Psychiatry. 1995;  37(7) 427-433
    CrossrefPubMedGoogle Scholar
  • 64 Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Risch S C, Thrivikraman K V, Lewine R L. Clozapine-induced EEG abnormalities and clinical response to clozapine.  J Neuropsychiatry Clin Neurosci. 1995;  7(4) 466-470
    PubMedGoogle Scholar
  • 65 Sajatovic M, DiGiovanni S K, Bastani B, Hattab H, Ramirez L F. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania.  Psychopharmacol Bull. 1996;  32(1) 55-61
    PubMedGoogle Scholar
  • 66 Schaffer C B, Schaffer L C. The use of risperidone in the treatment of bipolar disorder.  J Clin Psychiatry. 1996;  57(3) 136
    PubMedGoogle Scholar
  • 67 Jacobsen F M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder.  J Clin Psychiatry. 1995;  56(9) 423-429
    PubMedGoogle Scholar
  • 68 Schweitzer I. Does risperidone have a place in the treatment of nonschizophrenic patients?.  Int Clin Psychopharmacol. 2001;  16(1) 1-19
    PubMedGoogle Scholar
  • 69 Tohen M, Zarate Jr C A, Centorrino F, Hegarty J I, Froeschl M, Zarate S B. Risperidone in the treatment of mania.  J Clin Psychiatry. 1996;  57(6) 249-253
    PubMedGoogle Scholar
  • 70 Roose K, Gelders Y, Heylen S. Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.  Acta Psychiatr Belg. 1988;  88(3) 233-241
    PubMedGoogle Scholar
  • 71 McIntyre R, Young L T, Hasey G, Patelis-Siotis I, Jones B D. Risperidone treatment of bipolar disorder.  Can J Psychiatry. 1997;  42(1) 88-90
    PubMedGoogle Scholar
  • 72 Lane H Y, Chiu W C, Chang W H. Risperidone monotherapy for mania and depression.  Am J Psychiatry. 1999;  156(7) 1115
    PubMedGoogle Scholar
  • 73 Goodnick P J. Risperidone treatment of refractory acute mania.  J Clin Psychiatry. 1995;  56(9) 431-432
    PubMedGoogle Scholar
  • 74 Ghaemi S N, Sachs G S, Baldassano C F, Truman C J. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients.  Can J Psychiatry. 1997;  42(2) 196-199
    PubMedGoogle Scholar
  • 75 Singh A N, Catalan J. Risperidone in HIV-related manic psychosis.  Lancet. 1994;  344(8928) 1029-1030
    CrossrefPubMedGoogle Scholar
  • 76 Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.  J Clin Psychiatry. 1995;  56(11) 514-518
    PubMedGoogle Scholar
  • 77 Licht R W, Bysted M, Christensen H. Fixed-dosed risperidone in mania: an open experimental trial.  Int Clin Psychopharmacol. 2001;  16(2) 103-110
    PubMedGoogle Scholar
  • 78 Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.  Clin Neuropharmacol. 1998;  21(3) 176-180
    PubMedGoogle Scholar
  • 79 Ghaemi S N, Sachs G S. Long-term risperidone treatment in bipolar disorder: 6-month follow.  Int Clin Psychopharmacol. 1997;  12(6) 333-338
    PubMedGoogle Scholar
  • 80 Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J. Treatment of refractory rapid cycling bipolar disorder with risperidone.  J Clin Psychopharmacol. 1998;  18(2) 172-174
    CrossrefPubMedGoogle Scholar
  • 81 Dwight M M, Keck Jr P E, Stanton S P, Strakowski S M, McElroy S L. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder.  Lancet. 1994;  344(8921) 554-555
    CrossrefPubMedGoogle Scholar
  • 82 Keck Jr P E, Wilson D R, Strakowski S M, McElroy S L, Kizer D L, Balistreri T M, Holtman H M, DePriest M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.  J Clin Psychiatry. 1995;  56(10) 466-470
    PubMedGoogle Scholar
  • 83 Hillert A, Maier W, Wetzel H, Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - a functional approach.  Pharmacopsychiatry. 1992;  25(5) 213-217
    PubMedGoogle Scholar
  • 84 Aubry J M, Simon A E, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.  J Clin Psychiatry. 2000;  61(9) 649-655
    CrossrefPubMedGoogle Scholar
  • 85 Lane H Y, Lin Y C, Chang W H. Mania induced by risperidone: dose related?.  J Clin Psychiatry. 1998;  59(2) 85-86
    PubMedGoogle Scholar
  • 86 Schnierow B J, Graeber D A. Manic symptoms associated with initiation of risperidone.  Am J Psychiatry. 1996;  153(9) 1235-1236
    PubMedGoogle Scholar
  • 87 Tomlinson W C. Respiridone and mania.  Am J Psychiatry. 1996;  153(1) 132-133
    PubMedGoogle Scholar
  • 88 Khouzam H R, El-Gabalawi F. Treatment of bipolar I disorder in an adolescent with olanzapine.  J Child Adolesc Psychopharmacol. 2000;  10(2) 147-151
    PubMedGoogle Scholar
  • 89 Soutullo C A, Sorter M T, Foster K D, McElroy S L, Keck P E. Olanzapine in the treatment of adolescent acute mania: a report of seven cases.  J Affect Disord. 1999;  53(3) 279-283
    CrossrefPubMedGoogle Scholar
  • 90 Weisler R H, Ahearn E P, Davidson J R, Wallace C D. Adjunctive use of olanzapine in mood disorders: five case reports.  Ann Clin Psychiatry. 1997;  9(4) 259-262
    CrossrefPubMedGoogle Scholar
  • 91 Goodnick P J, Barrios C A. Use of olanzapine in non-psychotic psychiatric disorders.  Expert Opin Pharmacother. 2001;  2(4) 667-680
    CrossrefPubMedGoogle Scholar
  • 92 McElroy S L, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, Suppes T, Keck Jr P E, Leverich G S, Kmetz G F, Post R M. Olanzapine in treatment-resistant bipolar disorder.  J Affect Disord. 1998;  49(2) 119-122
    CrossrefPubMedGoogle Scholar
  • 93 Ananth J. Is olanzapine a mood stabilizer?.  Can J Psychiatry. 1999;  44(9) 927-928
    PubMedGoogle Scholar
  • 94 Guille C, Sachs G S, Ghaemi S N. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.  J Clin Psychiatry. 2000;  61(9) 638-642
    PubMedGoogle Scholar
  • 95 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.  Int Clin Psychopharmacol. 1999;  14(6) 339-343
    CrossrefPubMedGoogle Scholar
  • 96 Tohen M, Zarate C A, Centorrino F, Hegarty J, Zarate S M. Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. San Diego, California :Annual Meeting of the Amerian Psychiatric Association May 17 - 22, 1997
    Google Scholar
  • 97 Sharma V, Pistor L. Treatment of bipolar mixed state with olanzapine.  J Psychiatry Neurosci. 1999;  24(1) 40-44
    PubMedGoogle Scholar
  • 98 Zullino D, Baumann P. Olanzapine for mixed episodes of bipolar disorder.  J Psychopharmacol. 1999;  13(2) 198
    PubMedGoogle Scholar
  • 99 Ketter T A, Winsberg M E, DeGolia S G, Dunai M, Tate D L, Strong C M. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.  J Clin Psychiatry. 1998;  59(2) 83-85
    PubMedGoogle Scholar
  • 100 Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson G D, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group.  Arch Gen Psychiatry. 2000;  57(9) 841-849
    CrossrefPubMedGoogle Scholar
  • 101 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G, Petty F, Centorrino F, Wang R, Grundy S L, Greaney M G, Jacobs T G, David S R, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.  Am J Psychiatry. 1999;  156(5) 702-709
    PubMedGoogle Scholar
  • 102 Sanger T M, Grundy S L, Gibson P J, Namjoshi M A, Greaney M G, Tohen M F. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.  J Clin Psychiatry. 2001;  62(4) 273-281
    PubMedGoogle Scholar
  • 103 Zarate Jr C A, Narendran R, Tohen M, Greaney J J, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders.  J Clin Psychiatry. 1998;  59(1) 24-28
    CrossrefPubMedGoogle Scholar
  • 104 Ghaemi S N, Cherry E L, Katzow J A, Goodwin F K. Does olanzapine have antidepressant properties? A retrospective preliminary study.  Bipolar Disord. 2000;  2(3) 196-199
    CrossrefPubMedGoogle Scholar
  • 105 Fitz-Gerald M J, Pinkofsky H B, Brannon G, Dandridge E, Calhoun A. Olanzapine-induced mania.  Am J Psychiatry. 1999;  156(7) 1114
    PubMedGoogle Scholar
  • 106 Lindenmayer J P, Klebanov R. Olanzapine-induced manic-like syndrome.  J Clin Psychiatry. 1998;  59(6) 318-319
    PubMedGoogle Scholar
  • 107 Allison D B, Casey D E. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 Suppl 7 22-31
    PubMedGoogle Scholar
  • 108 Harada T, Otsuki S. Antimanic effect of zotepine.  Clin Ther. 1986;  8(4) 406-414
    PubMedGoogle Scholar
  • 109 Wolfersdorf M, Konig F, Straub R. Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol.  Neuropsychobiology. 1994;  29(4) 189-193
    PubMedGoogle Scholar
  • 110 Ghaemi S N, Katzow J J. The use of quetiapine for treatment-resistant bipolar disorder: a case series.  Ann Clin Psychiatry. 1999;  11(3) 137-140
    CrossrefPubMedGoogle Scholar
  • 111 Dunayevich E, Strakowski S M. Quetiapine for treatment-resistant mania.  Am J Psychiatry. 2000;  157(8) 1341
    CrossrefPubMedGoogle Scholar
  • 112 Zarate Jr C A, Rothschild A, Fletcher K E, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders.  J Clin Psychiatry. 2000;  61(3) 185-189
    PubMedGoogle Scholar
  • 113 Ghaemi S N. New treatments for bipolar disorder: the role of atypical neuroleptic agents.  J Clin Psychiatry. 2000;  61 Suppl 14 33-42
    PubMedGoogle Scholar
  • 114 McElroy S L, Keck Jr P E. Pharmacologic agents for the treatment of acute bipolar mania.  Biol Psychiatry. 2000;  48(6) 539-557
    CrossrefPubMedGoogle Scholar
  • 115 Ketter T A, Flockhart D A, Post R M, Denicoff K, Pazzaglia P J, Marangell L B, George M S, Callahan A M. The emerging role of cytochrome P450 3A in psychopharmacology.  J Clin Psychopharmacol. 1995;  15(6) 387-398
    CrossrefPubMedGoogle Scholar
  • 116 DeVane C L. Pharmacogenetics and drug metabolism of newer antidepressant agents.  J Clin Psychiatry. 1994;  55 Suppl 38-45
    PubMedGoogle Scholar
  • 117 Pollok B. Recent developments in drug metabolism of relevance to psychiatrists.  Harvard Rev Psychiatry. 1994;  55 (12) 38-45
    PubMedGoogle Scholar
  • 118 Meyer M C, Baldessarini R J, Goff D C, Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs.  Drug Saf. 1996;  15(5) 333-346
    PubMedGoogle Scholar
  • 119 Goff D C, Baldessarini R J. Drug interactions with antipsychotic agents.  J Clin Psychopharmacol. 1993;  13(1) 57-67
    PubMedGoogle Scholar
  • 120 Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs.  Epilepsia. 1999;  40 Suppl 10 71-76
    PubMedGoogle Scholar
  • 121 Prior T I, Chue P S, Tibbo P, Baker G B. Drug metabolism and atypical antipsychotics.  Eur Neuropsychopharmacol. 1999;  9(4) 301-309
    PubMedGoogle Scholar
  • 122 Wong Y W, Yeh C, Thyrum P T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.  J Clin Psychopharmacol. 2001;  21(1) 89-93
    CrossrefPubMedGoogle Scholar
  • 123 Lucas R A, Gilfillan D J, Bergstrom R F. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.  Eur J Clin Pharmacol. 1998;  54(8) 639-643
    CrossrefPubMedGoogle Scholar
  • 124 Wilson W H. Do anticonvulsants hinder clozapine treatment?.  Biol Psychiatry. 1995;  37(2) 132-133
    CrossrefPubMedGoogle Scholar
  • 125 Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Risch S C, Thrivikraman K V, Lewine R L. Clozapine-induced EEG abnormalities and clinical response to clozapine.  J Neuropsychiatry Clin Neurosci. 1995;  7(4) 466-470
    PubMedGoogle Scholar
  • 126 Arana G W, Goff D C, Friedman H, Ornsteen M, Greenblatt D J, Black B, Shader R I. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?.  Am J Psychiatry. 1986;  143(5) 650-651
    PubMedGoogle Scholar
  • 127 Kahn E M, Schulz S C, Perel J M, Alexander J E. Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia.  J Clin Psychopharmacol. 1990;  10(1) 54-57
    CrossrefPubMedGoogle Scholar
  • 128 Centorrino F, Baldessarini R J, Flood J G, Kando J C, Frankenburg F R. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites.  Am J Psychiatry. 1995;  152(4) 610-612
    PubMedGoogle Scholar
  • 129 Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine?.  Pharmacopsychiatry. 1993;  26(6) 262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 130 Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.  Ther Drug Monit. 1994;  16(4) 368-374
    PubMedGoogle Scholar
  • 131 Raitasuo V, Lehtovaara R, Huttunen M O. Carbamazepine and plasma levels of clozapine.  Am J Psychiatry. 1993;  150(1) 169
    PubMedGoogle Scholar
  • 132 Bourgeois B FD. Pharmacological interactions between valproate and other drugs.  Am J Med. 1988;  84 9-33
    PubMedGoogle Scholar
  • 133 Balfour J A, Bryson H M. Valproid acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy.  CNS Drugs. 1994;  2 144-173
    PubMedGoogle Scholar
  • 134 Kando J C, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders.  J Clin Psychiatry. 1994;  55(6) 255-257
    PubMedGoogle Scholar
  • 135 Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition.  Biol Psychiatry. 1994;  36(7) 487-488
    PubMedGoogle Scholar
  • 136 Centorrino F, Baldessarini R J, Kando J, Frankenburg F R, Volpicelli S A, Puopolo P R, Flood J G. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.  Am J Psychiatry. 1994;  151(1) 123-125
    CrossrefPubMedGoogle Scholar
  • 137 Emrich M, Okuma T, Muller A A. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica 1984
    Google Scholar
  • 138 Loudon J B, Waring H. Toxic reactions to lithium and haloperidol.  Lancet. 1976;  2(7994) 1088
    PubMedGoogle Scholar
  • 139 Jeffries J, Remington G, Wilkins J. The question of lithium/neuroleptic toxicity.  Can J Psychiatry. 1984;  29(7) 601-604
    PubMedGoogle Scholar
  • 140 Goldney R D, Spence N D. Safety of the combination of lithium and neuroleptic drugs.  Am J Psychiatry. 1984;  29 601-604
    PubMedGoogle Scholar
  • 141 Schou M. Long-lasting neurological sequelae after lithium intoxication.  Acta Psychiatr Scand. 1984;  70(6) 594-602
    CrossrefPubMedGoogle Scholar
  • 142 Addonizio G, Susman V L, Roth S D. Neuroleptic malignant syndrome: review and analysis of 115 cases.  Biol Psychiatry. 1987;  22(8) 1004-1020
    CrossrefPubMedGoogle Scholar
  • 143 Blake L M, Marks R C, Luchins D J. Reversible neurologic symptoms with clozapine and lithium.  J Clin Psychopharmacol. 1992;  12(4) 297-299
    PubMedGoogle Scholar
  • 144 Baldessarini R J, Stephens J H. Lithium carbonate for affective disorders. I. Clinical pharmacology and toxicology.  Arch Gen Psychiatry. 1970;  22(1) 72-77
    PubMedGoogle Scholar
  • 145 Garcia G, Crismon M L, Dorson P G. Seizures in two patients after the addition of lithium to a clozapine regimen.  J Clin Psychopharmacol. 1994;  14(6) 426-428
    PubMedGoogle Scholar
  • 146 Berk M. Lamotrigine and the treatment of mania in bipolar disorder.  Eur Neuropsychopharmacol. 1999;  9 Suppl 4 119-123
    CrossrefPubMedGoogle Scholar
  • 147 Normann C, Langosch J, Schaerer L O, Grunze H, Walden J. Treatment of acute mania with topiramate.  Am J Psychiatry. 1999;  156(12) 2014
    PubMedGoogle Scholar
  • 148 Ketter T A, Frye M A, Cora-Locatelli G, Kimbrell T A, Post R M. Metabolism and excretion of mood stabilizers and new anticonvulsants.  Cell Mol Neurobiol. 1999;  19(4) 511-532
    CrossrefPubMedGoogle Scholar
  • 149 Patsalos P N, Duncan J S. New antiepileptic drugs: a review of their current status and clinical potential.  CNS Dugs. 1994;  2 40-77
    PubMedGoogle Scholar
  • 150 Anderson G D, Graves N M. Drug interactions with anti-epileptic agents. Prevention and management.  CNS Drugs. 1994;  2 268-279
    PubMedGoogle Scholar
  • 151 Alldredge B K. Seizure risk with psychotropic drugs: clinical and pharmacokinetic considerations.  Neurology. 1999;  53 (Suppl. 2) 68-75
    PubMedGoogle Scholar
  • 152 Sproule B A, Naranjo C A, Brenmer K E, Hassan P C. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.  Clin Pharmacokinet. 1997;  33(6) 454-471
    CrossrefPubMedGoogle Scholar

Prof. Dr. Ch. Barnas

Klinische Abteilung für Allgemeine Psychiatrie · Univ.-Klinik für Psychiatrie

Währinger Gürtel 18-20

1090 Wien

Österreich

      >